Last reviewed · How we verify
NCT07523347
Efficacy and Safety of Oral Rivaroxaban in Cerebrosinovenous Thrombosis
NA trial testing Rivaroxaban in Cerebrosinovenous Thrombosis in 75 participants. Completed in 31 December 2025.
31 December 2025
Quick facts
| Lead sponsor | Muhammad Aamir Latif |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 75 |
| Start date | 1 December 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Rivaroxaban (rivaroxaban) — full drug profile →
- Warfarin (warfarin) — full drug profile →
Conditions studied
- Cerebrosinovenous Thrombosis — all drugs for Cerebrosinovenous Thrombosis →
Sponsor
Muhammad Aamir Latif — full company profile →
Who can join
Adults 2 Months to 18, any sex, with Cerebrosinovenous Thrombosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study seeks to fill the gaps regarding safety and efficacy of rivaroxaban and standard anticoagulant. therefore the current study was planned with the aim to determine the safety and efficacy of rivaroxaban and standard anticoagulant in the treatment of cerebrosinovenous thrombosis (CSVT).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07523347
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rivaroxaban
Trials testing the same drug.
- NCT06953726 — Comparing the Safety and Efficacy of Apixaban and Rivaroxaban · Phase 4 · not yet recruiting
- NCT07468448 — Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe · Phase 3 · not yet recruiting
- NCT07318610 — Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease · Phase 3 · not yet recruiting
- NCT07312851 — A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Parti · Phase 1 · recruiting
- NCT06961630 — Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction · EARLY_PHASE1 · recruiting
Other Muhammad Aamir Latif trials
Trials by the same sponsor.
- NCT07462182 — Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction · NA · not yet recruiting
- NCT07426744 — Antipyretic Therapy With and Without Cold Sponging · NA · not yet recruiting
- NCT07437391 — Effect of L-Carnitine Supplementation in Preterm Neonates · NA · recruiting
- NCT07313670 — Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock · NA · not yet recruiting
- NCT07305935 — Comparison of Early Caffeine Administration Vs Supportive Therapy in Preventing Acute Kidney Injury · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07523347 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Muhammad Aamir Latif
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07523347.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing